Key facts
- It has raised $26.9M; the latest was Later Stage VC ($26.9M) in Mar 2026.
- Notable investors include European Commission, High-Tech Gründerfonds, University of California, Brandenburg Kapital, CARMA FUND Management — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for KUPANDO
- ·The full record, as it builds
Funding rounds
No funding rounds for KUPANDO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KUPANDO
Developer of a biotechnology platform designed to stimulate innate immunity to address unmet needs in cancer and infectious diseases. The company offers dual TLR agonist therapies with innate immune-training capabilities, enabling patients with oncology and infectious disease conditions to have improved access to novel immune-activating treatments.
- Sector
- Healthcare
- HQ
- Schönefeld, Germany
- Founded
- 2018
- Employees
- 8
- Website
- kupando.com/
- Ownership
- Privately Held (backing)
KUPANDO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KUPANDO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KUPANDO in its N-PORT filings yet. We sweep new filings monthly.